Clinical Trial Update: Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) [Phase 3]

View source ↗

Summary

Phase 3 trial of MD1003 in progressive multiple sclerosis was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• MD1003 (biotin (high-dose))

Snippet

Sponsor: MedDay Pharmaceuticals SA | Conditions: Multiple Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2020-11-23